| Literature DB >> 33152324 |
Xiphias Ge Zhu1, Aleksey Chudnovskiy2, Lou Baudrier1, Benjamin Prizer1, Yuyang Liu1, Benjamin N Ostendorf3, Norihiro Yamaguchi3, Abolfozl Arab4, Bernardo Tavora3, Rebecca Timson1, Søren Heissel5, Elisa de Stanchina6, Henrik Molina5, Gabriel D Victora2, Hani Goodarzi4, Kıvanç Birsoy7.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) cells require substantial metabolic rewiring to overcome nutrient limitations and immune surveillance. However, the metabolic pathways necessary for pancreatic tumor growth in vivo are poorly understood. To address this, we performed metabolism-focused CRISPR screens in PDAC cells grown in culture or engrafted in immunocompetent mice. While most metabolic gene essentialities are unexpectedly similar under these conditions, a small fraction of metabolic genes are differentially required for tumor progression. Among these, loss of heme synthesis reduces tumor growth due to a limiting role of heme in vivo, an effect independent of tissue origin or immune system. Our screens also identify autophagy as a metabolic requirement for pancreatic tumor immune evasion. Mechanistically, autophagy protects cancer cells from CD8+ T cell killing through TNFα-induced cell death in vitro. Altogether, this resource provides metabolic dependencies arising from microenvironmental limitations and the immune system, nominating potential anti-cancer targets.Entities:
Keywords: cancer metabolism; in vivo CRISPR screen; pancreatic cancer; tumor immune evasion
Mesh:
Year: 2020 PMID: 33152324 PMCID: PMC7790894 DOI: 10.1016/j.cmet.2020.10.017
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287